How To Plan And Submit A Marketing Authorization Application: The EMA Perspective

Too few marketing authorization applications are submitted to the European Medicines Agency on time, leading to disruption and resourcing difficulties. The Pink Sheet examines initiatives taken in the recent past to address the issue and what companies need to be aware of to ensure the evaluation process is as efficient as possible.

Pushing Barriers
Companies can facilitate the efficient evaluation of their EU drug filings (Shutterstock)

More from Agency Leadership

More from Pathways & Standards